Webb M L, Meek T D
Department of Cardiovascular Biochemistry, Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, New Jersey 08543-400, USA.
Med Res Rev. 1997 Jan;17(1):17-67. doi: 10.1002/(sici)1098-1128(199701)17:1<17::aid-med2>3.0.co;2-w.
With the advent of the first generation of both selective and nonselective endothelin antagonists being a relatively recent event, the manifold therapeutic potentials of these compounds are only now being explored clinically. Undoubtedly, numerous clinical utilities for these compounds will soon be realized.